{domain:"www.qualitydigest.com",server:"169.47.211.87"} Skip to main content

        
User account menu
Main navigation
  • Topics
    • Customer Care
    • Regulated Industries
    • Research & Tech
    • Quality Improvement Tools
    • People Management
    • Metrology
    • Manufacturing
    • Roadshow
    • QMS & Standards
    • Statistical Methods
    • Resource Management
  • Videos/Webinars
    • All videos
    • Product Demos
    • Webinars
  • Advertise
    • Advertise
    • Submit B2B Press Release
    • Write for us
  • Metrology Hub
  • Training
  • Subscribe
  • Log in
Mobile Menu
  • Home
  • Topics
    • Customer Care
    • Regulated Industries
    • Research & Tech
    • Quality Improvement Tools
    • People Management
    • Metrology
    • Manufacturing
    • Roadshow
    • QMS & Standards
    • Statistical Methods
    • Supply Chain
    • Resource Management
  • Login / Subscribe
  • More...
    • All Features
    • All News
    • All Videos
    • Contact
    • Training

Trace-Level Testing, Validation Pressure, and the New Demands on Pharma Labs

Labs are under increasing pressure to balance trace-level accuracy, validation requirements, documentation, and faster development timelines

Muhammad Syafi Al-adam / Unsplash

Greg Rankin
Wed, 07/01/2026 - 12:02
  • Comment
  • RSS

Social Sharing block

  • Print
Body

As pharmaceutical manufacturers push toward lower detection limits, tighter impurity thresholds, and faster development cycles, elemental analysis has become a more critical part of quality and compliance.

ADVERTISEMENT

Regulatory frameworks such as U.S. Pharmacopeia (USP) <232>, USP <233>, and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q3D have formalized and intensified industry focus on elemental impurity testing, particularly for trace-level metals that might present patient safety risks even at very low concentrations.

USP <232> establishes limits for elemental impurities in pharmaceutical products, while USP <233> describes analytical procedures used to evaluate them. ICH Q3D adds a risk-based framework for controlling elemental impurities throughout the product life cycle. Together, these standards have pushed pharmaceutical laboratories toward increasingly sensitive analytical workflows, particularly ICP-MS and ICP-OES systems capable of trace-level detection.

 …

Want to continue?
Log in or create a FREE account.
Enter your username or email address
Enter the password that accompanies your username.
By logging in you agree to receive communication from Quality Digest. Privacy Policy.
Create a FREE account
Forgot My Password
Top Stories
Problem Solving and Continuous Improvement Are Not the Same
‘Not relevant’ is no longer an answer on climate change
AI Job Growth Claims Outrun the Evidence
How Many Units Should Be in the Metric System?
Your Innovation Problem May Not Be an Innovation Problem

Add new comment

Please login to comment.

© 2026 Quality Digest. Copyright on content held by Quality Digest or by individual authors. Contact Quality Digest for reprint information.
“Quality Digest" is a trademark owned by Quality Circle Institute Inc.

footer
  • Home
  • Print QD: 1995-2008
  • Print QD: 2008-2009
  • Videos
  • Privacy Policy
  • Write for us
footer second menu
  • Subscribe to Quality Digest
  • About Us
  • Contact Us